fphar-08-00546.pdf (285.4 kB)
Interplay of the quality of ciprofloxacin and antibiotic resistance in developing countries
journal contribution
posted on 2023-05-19, 10:22 authored by Sharma, D, Rahul PatelRahul Patel, Syed Razi ZaidiSyed Razi Zaidi, Sarker, MMR, Lean, QY, Ming, LCCiprofloxacin, a second generation broad spectrum fluoroquinolone, is active against both Gram-positive and Gram-negative bacteria. Ciprofloxacin has a high oral bioavailability and a large volume of distribution. It is used for the treatment of a wide range of infections including urinary tract infections caused by susceptible bacteria. However, the availability and use of substandard and spurious quality of oral ciprofloxacin formulations in the developing countries has been thought to have contributed toward increased risk of treatment failure and bacterial resistance. Therefore, quality control and bioequivalence studies of the commercially available oral ciprofloxacin formulations should be monitored. Appropriate actions should be taken against offending manufacturers in order to prevent the sale of substandard and spurious quality of ciprofloxacin formulations.
History
Publication title
Frontiers in PharmacologyVolume
8Article number
546Number
546Pagination
1-7ISSN
1663-9812Department/School
School of Pharmacy and PharmacologyPublisher
Frontiers Research FoundationPlace of publication
SwitzerlandRights statement
Copyright 2017 The Author(s) Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/Repository Status
- Open